Further detailed analyses of the posttranslational modifications of Gata3 and identification of responsible enzymes may lead to the discovery of novel therapeutic targets for Th2-mediated, IFNγ-involved chronic inflammatory disorders, including atopic dermatitis or chronic airway inflammatory disorders. Here, GATA3 is linked to atopic eczema.